RCKT Q3 2025 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RCKTRocket Pharmaceuticals, Inc.

$572M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$52M

Net Income

-$50M

EPS (Diluted)

$-0.45

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$50M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$368M

Total Liabilities

$54M

Stockholders' Equity

$314M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$52M	-$69M	+24.7%
Net Income	-$50M	-$67M	+24.6%